Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has reported a loss for its fourth fiscal quarter (ending December 31) of $-1.39 versus a loss $-1.52 for the same period a year ago. This result fell short of the consensus estimate of $-1.27 by $-0.12. For the latest four quarters through December 31, E.P.S. were $-6.29 versus $-8.25 for the same period a year ago.
Recent Price Action
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock rose slightly by 0.2% on 2/13/25. The stock closed at $43.52. NORMAL trading volume accompanied the advance. The stock has performed in line with the market over the last nine months and has declined -4.1% during the last week.
Current PriceTarget Research Rating
Ultragenyx Pharmaceutical has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Ultragenyx Pharmaceutical has a very low Appreciation Score of 4 but a neutral Power Rating of 53, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment